MK0952 in Patients With Mild-to-Moderate Alzheimer's Disease (0952-004)(COMPLETED)

MK0952 in Patients With Mild-to-Moderate Alzheimer's Disease

Status

Terminated

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00362024

Enrollment

Registered

2006-08-09

Start date

2006-11-30

Completion date

2007-11-30

Last updated

2016-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's Disease

Brief summary

MK0952 is a phosphodiesterase type IV (PDE4) inhibitor in development for improvement of cognitive impairment in mild-to-moderate Alzheimer's disease.

Interventions

DRUGMK0952

DRUGComparator: Placebo

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

55 Years to No maximum

Healthy volunteers

Inclusion criteria

* Male or females * Age \>/= 55 years, With mild-to-moderate AD, with MMSE between 18 and 26, inclusive, MHIS score \</= 4, Global CDR score of 1 or 2 * Who have a reliable informant/caregiver to accompany patient to all clinic visits * If using a symptomatic AD treatments, patients must be on stable dose for \>/= 6 months

Exclusion criteria

* Patients must not be living in nursing home or skilled nursing facility * Patients must not have current evidence and/or history of Crohn's disease, ulcerative colitis, proctitis, GI bleeding, mesenteric arteritis * Patients must not have current evidence and/or history of poorly-controlled hypertension, clinically significant cardiac arrhythmia, angina, or CHF * Patients must not have current evidence and/or history of a psychotic disorder or major untreated depressive disorder * Patients must not have current evidence and/or history of stroke or multiple lacunar infarcts, or neurological or neurodegenerative disorder (other than AD) * Various concomitant therapy restrictions

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026